Despite the EPS miss, the improved survival data strengthens the clinical case for IMNN-001. Monitor enrollment progress in the Phase 3 OVATION 3 trial and upcoming interim analyses as key catalysts. The recent capital raise extends the runway but further dilution may be needed before potential approval.
Price Chart
Executive Summary
Imunon reported a 2025 net loss of $14.5 million (EPS $-6.83), missing consensus by 55.9%, but highlighted improved Phase 2 survival data showing a 14.7-month overall survival benefit for its ovarian cancer therapy IMNN-001. The company raised $7.0 million in December 2025 and ended the year with $8.8 million in cash.
Key Financial Metrics
Key Facts
- Net loss for 2025 was $14.5 million, or $6.83 per share, compared to a net loss of $18.6 million, or $16.94 per share, in 2024
- Final Phase 2 data showed a median 14.7-month overall survival benefit (45.1 vs 30.4 months) for IMNN-001 plus chemotherapy vs chemotherapy alone
- Women receiving IMNN-001 plus PARP inhibitors showed a 24.2-month survival benefit (65.6 vs 41.4 months)
- Company completed a $7.0 million registered direct offering in December 2025
- Cash and cash equivalents were $8.8 million as of December 31, 2025
Financial Impact
Net loss narrowed to $14.5M from $18.6M year-over-year, but EPS of $-6.83 missed consensus of $-1.28 by 55.9%
Risk Factors
- EPS miss of 55.9% indicates ongoing funding challenges despite cost reductions
- Phase 3 trial success is not guaranteed despite promising Phase 2 data
- Additional capital raises could lead to shareholder dilution
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 6 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001493152-26-013816 |
| Document: form8-k.htm | 0001493152-26-013816 |
| Document: 0001493152-26-013816-index-headers.html | 0001493152-26-013816 |
| Document: 0001493152-26-013816-index.html | 0001493152-26-013816 |
| Document: 0001493152-26-013816.txt | 0001493152-26-013816 |
| 8-K Data (Synthetic) | 0001493152-26-013816 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 27, 2026 today | S-1 | $1.22 | awaiting T+20 | — | $0.8800 (+27.87%) |
Oct 27, 2026 today | 8-K | $1.25 | awaiting T+20 | — | $0.8800 (−29.60%) |
Oct 21, 2026 6d ago | 8-K | $1.19 | awaiting T+20 | — | $0.8800 (−26.05%) |
Sep 29, 2026 28d ago | 8-K | $1.34 $0.8762 | ▲ +34.37% | ▲ +35.08% | $0.8800 (+34.08%) |
Aug 11, 2026 11w ago | 8-K | $1.61 $1.45 | ▼ −9.94% | ▼ −8.04% | $0.8800 (−45.34%) |
Aug 11, 2026 11w ago | 8-K | $1.61 $1.51 | ▼ −6.21% | ▼ −5.15% | $0.8800 (−45.34%) |
Jun 30, 2026 17w ago | 8-K | $1.88 $1.54 | ▼ −18.09% | ▼ −15.90% | $0.8800 (−53.19%) |
Jun 16, 2026 19w ago | 8-K | $1.86 $1.89 | ▲ +1.61% | ▲ +0.30% | $0.8800 (−52.69%) |
Jun 4, 2026 20w ago | 8-K | $2.10 $1.91 | ▲ +9.05% | ▲ +7.68% | $0.8800 (+58.10%) |
May 12, 2026 24w ago | 8-K | $2.70 $1.98 | ▼ −26.67% | ▼ −24.94% | $0.8800 (−67.41%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers